Literature DB >> 10498627

Erythropoietin receptor mutations associated with familial erythrocytosis cause hypersensitivity to erythropoietin in the heterozygous state.

S S Watowich1, X Xie, U Klingmuller, J Kere, M Lindlof, S Berglund, A de la Chapelle.   

Abstract

Inherited mutations in the erythropoietin receptor (EPOR) causing premature termination of the receptor cytoplasmic region are associated with dominant familial erythrocytosis (FE), a benign clinical condition characterized by hypersensitivity of erythroid progenitor cells to EPO and low serum EPO (S-EPO) levels. We describe a Swedish family with dominant FE in which erythrocytosis segregates with a new truncation in the negative control domain of the EPOR. We show that cells engineered to concomitantly express the wild-type (WT) EPOR and mutant EPORs associated with FE (FE EPORs) are hypersensitive to EPO-stimulated proliferation and activation of Jak2 and Stat5. These results demonstrate that FE is caused by hyperresponsiveness of receptor-mediated signaling pathways and that this is dominant with respect to WT EPOR signaling.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10498627

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

Review 1.  Eliminative signaling by Janus kinases: role in the downregulation of associated receptors.

Authors:  Christopher J Carbone; Serge Y Fuchs
Journal:  J Cell Biochem       Date:  2014-01       Impact factor: 4.429

2.  A case of primary familial congenital polycythemia with a novel EPOR mutation: possible spontaneous remission/alleviation by menstrual bleeding.

Authors:  Naohisa Toriumi; Makoto Kaneda; Naoki Hatakeyama; Hiromi Manabe; Kazuki Okajima; Yukari Sakurai; Masayo Yamamoto; Takeo Sarashina; Katsuya Ikuta; Hiroshi Azuma
Journal:  Int J Hematol       Date:  2018-04-05       Impact factor: 2.490

Review 3.  Erythropoietin Receptor Signaling and Lipid Rafts.

Authors:  Kathy McGraw; Alan List
Journal:  Vitam Horm       Date:  2017-03-23       Impact factor: 3.421

Review 4.  Hematopoietic growth factors, signaling and the chronic myeloproliferative disorders.

Authors:  Kenneth Kaushansky
Journal:  Cytokine Growth Factor Rev       Date:  2006-10-20       Impact factor: 7.638

5.  A novel mutation of the erythropoietin receptor gene associated with primary familial and congenital polycythaemia.

Authors:  Kacey O'Rourke; David J Fairbairn; Kathryn A Jackson; Kirk L Morris; Siok-Keen Tey; Glen A Kennedy
Journal:  Int J Hematol       Date:  2011-03-25       Impact factor: 2.490

Review 6.  The erythropoietin receptor: molecular structure and hematopoietic signaling pathways.

Authors:  Stephanie S Watowich
Journal:  J Investig Med       Date:  2011-10       Impact factor: 2.895

7.  Hematopoietic cell survival signals are elicited through non-tyrosine-containing sequences in the membrane-proximal region of the erythropoietin receptor (EPOR) by a Stat5-dependent pathway.

Authors:  Donghoon Yoon; Stephanie S Watowich
Journal:  Exp Hematol       Date:  2003-12       Impact factor: 3.084

8.  EPO receptor gain-of-function causes hereditary polycythemia, alters CD34 cell differentiation and increases circulating endothelial precursors.

Authors:  Silverio Perrotta; Valeria Cucciolla; Marcella Ferraro; Luisa Ronzoni; Annunziata Tramontano; Francesca Rossi; Anna Chiara Scudieri; Adriana Borriello; Domenico Roberti; Bruno Nobili; Maria Domenica Cappellini; Adriana Oliva; Giovanni Amendola; Anna Rita Migliaccio; Patrizia Mancuso; Ines Martin-Padura; Francesco Bertolini; Donghoon Yoon; Josef T Prchal; Fulvio Della Ragione
Journal:  PLoS One       Date:  2010-08-05       Impact factor: 3.240

Review 9.  Advances in understanding the pathogenesis of primary familial and congenital polycythaemia.

Authors:  Lily J Huang; Yu-Min Shen; Gamze B Bulut
Journal:  Br J Haematol       Date:  2010-01-20       Impact factor: 6.998

10.  Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation.

Authors:  Jacob P Laubach; Ping Fu; Xiaohong Jiang; Kelly H Salter; Anil Potti; Murat O Arcasoy
Journal:  Exp Hematol       Date:  2009-10-06       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.